Targeting pathogenic mechanisms in gMG: From complement- and FcRn-directed therapies to B- and T-cell-targeted approaches

touchTALKS for touchNEUROLOGY Listen to an autoimmune neuromuscular disease expert review the unmet needs for patients with generalized myasthenia gravis and explain how emerging targeted therapies address underlying disease mechanisms to improve patient outcomes. The expert Dr. Richard Nowak, Yale School of Medicine, New Haven, CT, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.    For further information, visit our website: https://touchneurologyime.org/targeted-therapies-in-gmg/